country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-132258A

Copy Link Print Information

Mirvetuximab soravtansine (solution)

(Synonyms: IMGN853 (solution))

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage.

For research use only. We do not sell to patients.

Purity: 97.25%
CAS No.: 1453084-37-1
Molecular Weight:150000 (average)

Storage:

-80°C, protect from light

Mirvetuximab soravtansine (solution) Chemical Structure

CAS No.: 1453084-37-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biological Activity
- Description
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

Mirvetuximab soravtansine (IMGN853; 8 nM; 6 h; IGROV-1 cells) combined with Carboplatin (HY-17393) promotes synergistic growth inhibitory effects and cell cycle perturbations in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mirvetuximab soravtansine (IMGN853; 5 mg/kg; i.v.; female severe combined immunodeficient (SCID) mice with patient-derived xenografts) potentiates the antitumor activity of Carboplatin in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1453084-37-1
Appearance Liquid
Molecular Weight 150000 (average)
Color Colorless to light yellow
SMILES

[Mirvetuximab soravtansine (solution)]
Synonyms

IMGN853 (solution)
Shipping

Shipping with dry ice.
Storage

-80°C, protect from light

Publications (3)

All Cell Proliferation/Viability AssayApoptosis AnalysisBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Anal Chem

Direct Visualization and Quantitative Modeling of Mass Transport Limitation in Biomolecular Kinetics via Imaging-Based Meta-SPR. [Abstract]

2026 Mar 24;98(11):8382-8393. PMID: 41814478
Cells

Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells. [Abstract]

2025 Feb 15;14(4):287. PMID: 39996761

Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287. [Abstract]

Mirvetuximab soravtansine (MIRV; 1.56-50 nM; 72 h). TCam2_R_SK cisplatin-resistant seminoma cells were treated with increasing doses of MIRV in vitro.

Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287. [Abstract]

Mirvetuximab soravtansine (MIRV; 12.5 nM; 0-72 h). Green fluorescent NLG-2102Ep_R_NL cells were cultured, whether alone or in coculture, with red fluorescent NLR-NOY1_R_SK cells with or without 12.5 nM MIRV. The cell number of the green 2102Ep_R_NL cells was evaluated using live-cell imaging in a kinetic proliferation assay.

Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287. [Abstract]

Mirvetuximab soravtansine (MIRV; 3.13-12.5 nM; 72 h). Live-cell imaging assays confirmed a significant decrease in the cell number of NLR-JEG3_R_SK choriocarcinoma cells upon treatment with a 3.13nM dose of MIRV.

Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287. [Abstract]

Mirvetuximab soravtansine (MIRV; 500 nM; 96 h). Induction of apoptosis via MIRV in cisplatin-resistant NT2_R_SK cells. NT2_R_SK (EC) cells were treated with 500 nM of MIRV or 2.5 µM of CPT in vitro.

Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287. [Abstract]

Mirvetuximab soravtansine (MIRV; 1.56-50 nM; 72 h). MIRV induced a decrease in cell impedance, as a readout of cytolysis was determined in a kinetic-based impedance assay.
ACS Omega

Evaluation of Antibody-Drug Conjugate Performances Using a Novel HPLC-DAD Method for Tumor-Specific Detection of DM4 and S‑Methyl-DM4. [Abstract]

2025 Oct 15;10(42):50382-50393. PMID: 41179189

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (268 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ponte JF, et, al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016 Dec;18(12):775-784. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Mirvetuximab soravtansine (solution)

3 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Purity & Documentation
References

1/16
1/16

Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287. [Abstract]

Customer Validation
Mirvetuximab soravtansine (MIRV; 1.56-50 nM; 72 h). TCam2_R_SK cisplatin-resistant seminoma cells were treated with increasing doses of MIRV in vitro.
1/16

Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287. [Abstract]

Customer Validation
Mirvetuximab soravtansine (MIRV; 12.5 nM; 0-72 h). Green fluorescent NLG-2102Ep_R_NL cells were cultured, whether alone or in coculture, with red fluorescent NLR-NOY1_R_SK cells with or without 12.5 nM MIRV. The cell number of the green 2102Ep_R_NL cells was evaluated using live-cell imaging in a kinetic proliferation assay.
1/16

Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287. [Abstract]

Customer Validation
Mirvetuximab soravtansine (MIRV; 3.13-12.5 nM; 72 h). Live-cell imaging assays confirmed a significant decrease in the cell number of NLR-JEG3_R_SK choriocarcinoma cells upon treatment with a 3.13nM dose of MIRV.
1/16

Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287. [Abstract]

Customer Validation
Mirvetuximab soravtansine (MIRV; 500 nM; 96 h). Induction of apoptosis via MIRV in cisplatin-resistant NT2_R_SK cells. NT2_R_SK (EC) cells were treated with 500 nM of MIRV or 2.5 µM of CPT in vitro.
1/16

Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287. [Abstract]

Customer Validation
Mirvetuximab soravtansine (MIRV; 1.56-50 nM; 72 h). MIRV induced a decrease in cell impedance, as a readout of cytolysis was determined in a kinetic-based impedance assay.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Mirvetuximab soravtansine (solution)

Publications Citing Use of MedChemExpress (MCE) Mirvetuximab soravtansine (solution)

Biological Activity

Chemical Information

Publications (3)

Purity & Documentation

References

Calculators

Help & FAQs

Mirvetuximab soravtansine (solution) Related Classifications

HY-132258A Related Classifications